Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell.
## Primary Indications
* Short-term treatment (up to 8 weeks) of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison (ZE) syndrome.
* Prophylaxis of stress-induced upper GI bleeding (off-label/institutional protocol dependent).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO/IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg PO once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg/day have been used. Titrate based on gastric acid output.
* **Stress Ulcer Prophylaxis:** Typically 40 mg IV daily; follow local institutional stewardship protocols.
## Pediatric Dosing
* **GERD/Erosive Esophagitis (5 years and older):**
* 15 kg to <40 kg: 20 mg once daily.
* 40 kg or greater: 40 mg once daily.
* **Safety/Efficacy:** Not established for children <5 years.
## Dose Adjustments
* **Hepatic Impairment:** Reduce frequency or avoid if possible in severe impairment. No specific adjustment required for mild to moderate hepatic impairment in label labeling, but caution is advised.
* **Renal Impairment:** No dosage adjustment necessary.
* **Geriatric:** No dosage adjustment necessary.
## Contraindications
* Hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole).
* Concurrent use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, injection site reactions (with IV).
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), bone fractures (long-term use), hypomagnesemia, vitamin B12 deficiency (long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus.
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of atazanavir, nelfinavir, iron salts, and certain azole antifungals (e.g., ketoconazole).
* **Methotrexate:** May increase methotrexate levels, particularly in high-dose therapy. Monitor levels.
* **Warfarin:** Potential for increased INR/prothrombin time; monitor closely upon initiation or discontinuation.
## Monitoring
* **Clinical:** Monitor for signs of enteric infection (e.g., severe/persistent diarrhea).
* **Labs:** Periodically monitor magnesium, B12, and electrolytes during long-term therapy (>1 year or chronic use). Monitor renal function if adverse symptoms arise.
* **Symptom Resolution:** Re-evaluate need for ongoing therapy if symptoms do not improve.
## Clinical Pearls
* **Administration:** IV pantoprazole should be administered as a 15-minute infusion or bolus injection (follow local policy).
* **Deprescribing:** Utilize "PPI tapering" protocols for patients on long-term therapy without a definitive indication to mitigate risks of rebound hypersecretion and nutrient malabsorption.
* **Formulation:** Delayed-release tablets must be swallowed whole; do not crush, split, or chew.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution; always consult local institutional protocols, current package inserts, and evidence-based clinical resources (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
